BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
June 14, 2006
View Archived Issues
Aegerion's Series A Adds $22M For Cholesterol-Lowering Work
In its first financing since it was founded in February 2005, Aegerion Pharmaceuticals Inc. raised $22.5 million in an oversubscribed Series A round to fund Phase II development of its lead dyslipidemia drug, AEGR 733. (BioWorld Today)
Read More
Centocor Evaluating ViaCell's Stem Cells In Cardiac Disease
Read More
Attractiveness Of AIM Market Being Showcased To Biotechs
Read More
United Therapeutics Signs PAH Licensing Deal With Supernus
Read More
Clinic Roundup
Read More
Other News To Note
Read More